Amprion announced new strategic growth initiatives aimed at broadening the availability of its Saamplify test, which detects misfolded alpha-synuclein protein linked to neurodegenerative diseases. According to the company, Saamplify is designed to aid in diagnosing conditions such as Parkinson’s disease and dementia with Lewy bodies.
The company said it plans to strengthen partnerships with healthcare systems and clinical research organizations to integrate the test into routine care and clinical trials. Amprion claims these efforts could support earlier diagnosis and intervention, potentially improving patient outcomes.
Amprion also noted it will focus on educating clinicians and researchers about the clinical utility of the Saamplify test. The company claims its assay offers high sensitivity and specificity, distinguishing it from other diagnostic tools.
As part of its strategy, the company stated it aims to expand laboratory capacity and streamline testing workflows to meet rising demand. Amprion did not disclose financial projections but said the initiatives align with its mission to transform the diagnosis and management of neurodegenerative diseases.
Amprion claims these measures will help address unmet needs in neurology by enabling better identification of disease at earlier stages, supporting both patient care and the development of targeted therapies.
